BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update

BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -

- Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -

- Management to host conference call today, May 27, at 8:30 am EDT -

TEL AVIV, Israel, May 27, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended March 31, 2026, and provided a corporate update.

"Since our last quarterly update, we achieved a significant milestone for our company and for the GLIX1 development program with the dosing of the first patient in our Phase 1/2a clinical trial of GLIX1 in glioblastoma," stated Philip Serlin, Chief Executive Officer of BioLineRx. "We are also very encouraged by compelling new pre-clinical data showing that GLIX1 demonstrated robust dose-dependent tumor-growth inhibition and survival benefit in orthotopic cell-derived xenograft (CDX) GBM models. Furthermore, in a newly completed subcutaneous TMZ-resistant patient-derived xenograft (PDX) GBM model, GLIX1 demonstrated a robust anti-tumor effect while no effect was observed with TMZ, highlighting the potential to address the very high unmet need in GBM."

"In the coming days, we look forward to engaging with the broader oncology community at this year's ASCO meeting with two abstracts featuring GLIX1. The abstracts highlight its novel mechanism of action and provide strong rationale for the development of GLIX1 in GBM as well as in other cancers. They also highlight that in safety studies in animals GLIX1 was safe up to the highest feasible doses tested, supporting the combination with other anti-cancer agents. Furthermore, the abstracts highlight the compelling mechanistic rationale for combining GLIX1 with PARP inhibitors supported by synergistic effect in cell lines across diverse cancers including from tumor types typically less responsive to PARP inhibition."

Financial Updates

Development Updates

GLIX1

Motixafortide

Pancreatic Ductal Adenocarcinoma (mPDAC)

APHEXDA Performance Update

Financial Results for the Quarter ended March 31, 2026

Conference Call and Webcast Information

To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 28, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial was initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and developed by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at  www.biolinerx.com, or on  LinkedIn.

Forward Looking Statement

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the expectations with regard to the planned Phase 1/2a GLIX1 clinical trial, expected timing of a clinical readout, and BioLineRx's business strategy. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance GLIX1 and motixafortide into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1 and motixafortide will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for GLIX1 and motixafortide and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable manner and whether GLIX1 and motixafortide receives adequate reimbursement from third.-party payors; BioLineRx's ability to establish, manage, and maintain corporate collaborations, as well as the ability of BioLineRx's collaborators to execute on their development and commercialization plans; BioLineRx's ability to integrate new therapeutic candidates and new personnel, as well as new collaborations; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection that BioLineRx's is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its need for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; BioLineRx's ability to maintain the listing of its ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx's business which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts:

United States

Chuck Padala

LifeSci Advisors, LLC

[email protected]

Israel

Moran Meir

LifeSci Advisors, LLC

[email protected]

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

(UNAUDITED)

December 31,

March 31,

2025

2026

in USD thousands

Assets

CURRENT ASSETS

Cash and cash equivalents

3,250

2,504

Short-term bank deposits

17,626

14,849

Prepaid expenses

201

181

Other receivables

456

1,891

Inventory

2,148

2,157

Total current assets

23,681

21,582

NON-CURRENT ASSETS

Property and equipment, net

160

146

Right-of-use assets, net

696

721

Intangible assets, net

16,368

16,348

Total non-current assets

17,224

17,215

Total assets

40,905

38,797

Liabilities and equity

CURRENT LIABILITIES

Current maturities of long-term loan

4,479

Accounts payable and accruals:

Trade

3,493

4,905

Other

1,743

2,249

Current maturities of lease liabilities

234

253

Warrants

2,174

1,738

Total current liabilities

12,123

13,624

NON-CURRENT LIABILITIES

Long-term loan, net of current maturities

4,460

3,359

Lease liabilities

977

979

Total non-current liabilities

5,437

4,338

COMMITMENTS AND CONTINGENT LIABILITIES

Total liabilities

17,560

17,962

EQUITY

Equity attributable to owners of the Company:

Ordinary shares

73,428

Share premium

327,584

Warrants

3,686

Capital reserve

15,916

15,994

Other comprehensive loss

(1,416)

Accumulated deficit

(401,002)

(402,603)

Total equity attributable to owners of the Company

18,196

16,673

Non-controlling interest

5,149

4,162

Total equity

23,345

20,835

Total liabilities and equity

40,905

38,797

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(UNAUDITED)

Three months ended March 31,

2025

2026

in USD thousands

ROYALTY REVENUES

255

477

COST OF REVENUES

(34)

(95)

GROSS PROFIT

221

382

RESEARCH AND DEVELOPMENT EXPENSES

(1,623)

(2,528)

GENERAL AND ADMINISTRATIVE EXPENSES

(989)

(858)

OPERATING LOSS

(2,391)

(3,004)

NON-OPERATING INCOME, NET

7,644

458

FINANCIAL INCOME

294

208

FINANCIAL EXPENSES

(420)

(250)

NET INCOME (LOSS) AND COMPREHENSIVE INCOME

(LOSS)

5,127

(2,588)

ATTRIBUTION OF NET INCOME (LOSS) AND

COMPREHENSIVE INCOME (LOSS)

To owners of the Company

5,127

(1,601)

To non-controlling interests

(987)

5,127

(2,588)

in USD

EARNINGS (LOSS) PER ORDINARY SHARE – BASIC AND

DILUTED ATTRIBUTABLE TO OWNERS OF THE

COMPANY

0.00

(0.00)

WEIGHTED AVERAGE NUMBER OF SHARES USED IN

CALCULATION OF BASIC AND DILUTED EARNINGS

(LOSS) PER ORDINARY SHARE

2,217,728,234

2,660,228,740

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)

Equity attributable to owners of the Company

Ordinary shares

premium

Warrants

Capital

reserve

Other

comprehensive

loss

Accumulated

deficit

Non-

controlling

interest

Total

in shares 000's

in USD thousands

BALANCE AT JANUARY 1, 2025

1,336,670

38,097

353,693

5,367

17,547

(1,416)

(399,827)

13,461

CHANGES FOR THREE MONTHS ENDED

MARCH 31, 2025:

Issuance of share capital, pre-funded

warrants and warrants, net

600,128

16,415

(14,836)

501

2,080

Pre-funded warrants exercised

295,804

8,058

(5,876)

(2,182)

Employee stock options expired

646

(646)

Share-based compensation

194

Comprehensive income for the year

5,127

BALANCE AT MARCH 31, 2025

2,232,602

62,570

333,627

3,686

17,095

(1,416)

(394,700)

20,862

Equity attributable to owners of the Company

Ordinary shares

premium

Warrants

Capital

reserve

Other

comprehensive

loss

Accumulated

deficit

Non-

controlling

interest

Total

in shares 000's

in USD thousands

BALANCE AT JANUARY 1, 2026

2,610,814

73,428

327,584

3,686

15,916

(1,416)

(401,002)

5,149

23,345

CHANGES FOR THREE MONTHS

ENDED MARCH 31, 2026:

Share-based compensation

Comprehensive loss for the year

(1,601)

(987)

(2,588)

BALANCE AT MARCH 31, 2026

2,610,814

73,428

327,584

3,686

15,994

(1,416)

(402,603)

4,162

20,835

BioLineRx Ltd.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three months ended March 31,

2025

2026

in USD thousands

CASH FLOWS - OPERATING ACTIVITIES

Comprehensive income (loss) for the period

5,127

(2,588)

Adjustments required to reflect net cash used in operating activities

(see appendix below)

(7,718)

308

Net cash used in operating activities

(2,591)

(2,280)

CASH FLOWS - INVESTING ACTIVITIES

Investments in short-term deposits

(12,307)

(5,181)

Maturities of short-term deposits

4,130

7,890

Purchase of property and equipment

(6)

Net cash provided by (used in) investing activities

(8,177)

2,703

CASH FLOWS - FINANCING ACTIVITIES

Issuance of share capital, pre-funded warrants and warrants, net of

issuance costs

10,697

Repayments of loan

(1,120)

Repayments of lease liabilities

(127)

(60)

Net cash provided by (used in) financing activities

9,450

(1,180)

DECREASE IN CASH AND CASH EQUIVALENTS

(1,318)

(757)

CASH AND CASH EQUIVALENTS - BEGINNING

OF PERIOD

10,436

3,250

EXCHANGE DIFFERENCES ON CASH AND CASH

EQUIVALENTS

(82)

CASH AND CASH EQUIVALENTS - END OF PERIOD

9,036

2,504

BioLineRx Ltd.

APPENDIX TO CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three months ended March 31,

2025

2026

in USD thousands

APPENDIX

Adjustments required to reflect net cash used in operating

activities:

Income and expenses not involving cash flows:

Depreciation and amortization

165

Exchange differences on cash and cash equivalents

(11)

Fair value adjustments of warrants

(8,311)

(436)

Share-based compensation

194

Interest and exchange differences on short-term deposits

(30)

Warrant issuance costs

702

Exchange differences on lease liabilities

(7)

(7,205)

(205)

Changes in operating asset and liability items:

Decrease in trade receivables

1,007

Increase in inventory

(170)

(9)

Decrease (increase) in prepaid expenses and other

receivables

1,157

(1,461)

Increase (decrease) in accounts payable and accruals

(2,507)

1,937

(513)

513

(7,718)

308

Supplemental information on interest received in cash

236

259

Supplemental information on interest paid in cash

361

245

Supplemental information on non-cash transactions:

Changes in right-of-use asset and lease liabilities

Warrant issuance costs

237

Logo - https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

SOURCE BioLineRx Ltd.